fda glp-1 compounding enforcement news National Hispanic Medical Association | The federal government is stepping up to stop counterfeit weight-loss drugs. In 2025, bipartisan lawmakers urged stronger FDA Moves to Restrict Mass-Marketed

doi: 10.3389/fphar.2025.1704083 Received 12 September 2025 Revised 16 December 2025 Accepted 18 December 2025 Published 21 January 2026 Volume 16 - 2025 Edited by Chen Ling, Fudan University, China Reviewed by Wentao Jia, Changhai Hospital, China Jie Cheng, Jiangsu University of Science and Technology, China Updates Copyright 2026 Li, Zhang, Li and Zheng

The medication is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that works by enhancing glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying

The calculator is an education tool, and your actual plan is always set by a licensed provider

Pregnant women, those with severe liver or kidney disease, and people on blood thinners should seek medical clearance